Who are Regular management+Levosimendan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levosimendan Injection, Levosimontane injection, Levosimendan infusion, epinephrine and levosimendan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/regular-management-levosimendan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Regular management+Levosimendan — Competitive Intelligence Brief

Regular management+Levosimendan (Regular management+Levosimendan) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium sensitizer / Inotropic agent. Area: Cardiovascular.

marketed Calcium sensitizer / Inotropic agent Cardiac troponin C Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Regular management+Levosimendan (Regular management+Levosimendan) — Qilu Hospital of Shandong University. Levosimendan is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, used as adjunctive therapy in acute decompensated heart failure.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Regular management+Levosimendan TARGET	Regular management+Levosimendan	Qilu Hospital of Shandong University	marketed	Calcium sensitizer / Inotropic agent	Cardiac troponin C
Levosimendan Injection	Levosimendan Injection	Peking University Third Hospital	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
Levosimontane injection	Levosimontane injection	Qilu Hospital of Shandong University	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
Levosimendan infusion	Levosimendan infusion	AHEPA University Hospital	marketed	Calcium sensitizer / inodilator	Cardiac troponin C; ATP-sensitive potassium channels
epinephrine and levosimendan	epinephrine and levosimendan	Federal University of Juiz de Fora	marketed	Inotropic agent combination	Adrenergic receptors (alpha-1, beta-1) and cardiac troponin C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium sensitizer / Inotropic agent class)

Qilu Hospital of Shandong University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Regular management+Levosimendan — Competitive Intelligence Brief. https://druglandscape.com/ci/regular-management-levosimendan. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab